Bayer HealthCare and Onyx Pharmaceuticals have filed regulatory applications with the FDA and the European Medicines Agency for approval to market Nexavar, or sorafenib, as a treatment for locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The applications were based on data from a late-stage trial showing that the drug significantly improved progression-free survival compared with a placebo.
Bayer, Onyx submit cancer drug Nexavar for U.S., EU approval
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Assistant Vice President - Dental Director||
|Vice President of Finance||
Urban Health Plan, Inc.